Method of anoxia treatment using prostaglandin analogues

Claim 1

A method for the prevention or treatment of anoxia of brain cells in a mammalian host which comprises administering to a host subject to, or suffering from said anoxia, an effective amount of a prostaglandin derivative selected from a PGI 1 derivative of the formula: ##STR9## wherein R 1 represents a hydrogen atom or a lower alkyl group and R 2 represents a 2-methylhexyl group, a 3-propylcyclopentyl group, a 3-butylcyclopentyl group or a 4-propylcyclohexyl group, a PGI 2 derivative of the formula: ##STR10## wherein R 3 represents a hydrogen atom or a lower alkyl group and R 4 represents a 2-methylhexyl group, a cyclopentyl group, a 3-propylcyclopentyl group or a cyclohexyl group, a PGI 2 derivative of the formula: ##STR11## wherein R 5 represents a lower alkyl group and R 6 represents a pentyl group, a 1-methylpentyl group, a 1-methyl-5-chloropentyl group, a 2-methyl-5-chloropentyl group, a 3-ethylcyclopentyl group, a 3-propylcyclopentyl group, a 3-butylcyclopentyl group, a 3-(2-chloroethyl)cyclopentyl group, a cyclohexyl group, a 4-ethylcyclohexyl group or a cyclohexylmethyl group, or a PGE 1 derivative of the formula: ##STR12## wherein X represents a methylene group or a carbonyl group, and (i) when X represents a methylene group, Y represents an ethylene group or a trans-vinylene group, R 7 represents a carboxyl group or a lower alkoxycarbonyl group and R 8 represents a 2-methylhexyl group or a 1-cyclohexylethyl group, and (ii) when X represents a carbonyl group, Y represents an ethylene group, R 7 represents a carboxyl group, a lower alkoxycarbonyl group, a glycoloyl group or a hydroxymethyl group and R 8 represents a 2-methylhexyl group, a cyclopentyl group, a 3-propylcyclopentyl group or a 3-butylcyclopentyl group, the double bonds between C 13 -C 14 in formulae (I), (II), (III) and (IV) being trans, the configuration at C 5 in formulae II and III being E or Z or a mixture thereof, the hydroxy groups attached to the C 11 position in formulae (I), (II), (III) and (IV) being in α-configuration and the hydroxy groups attached to the C 15 position in formulae (I), (II), (III) and (IV) being in α- or β-configuration, or a mixture thereof, or a cyclodextrin clathrate of a derivative of formula (I), (II), (III) or (IV) or, when R 1 in formula (I) or R 3 in formula (II) represents a hydrogen atom, or when R 7 in formula (IV) represents a carboxy group, a non-toxic salt thereof.

Claim 2

A method for the prevention or treatment of anoxia of brain cells in a mammalian host which comprises administering to a host subject to, or suffering from said anoxia, an effective amount of a prostaglandin derivative selected from a PGI 1 derivative of the formula: ##STR9## wherein R 1 represents a hydrogen atom or a lower alkyl group and R 2 represents a 2-methylhexyl group, a 3-propylcyclopentyl group, a 3-butylcyclopentyl group or a 4-propylcyclohexyl group, a PGI 2 derivative of the formula: ##STR10## wherein R 3 represents a hydrogen atom or a lower alkyl group and R 4 represents a 2-methylhexyl group, a cyclopentyl group, a 3-propylcyclopentyl group or a cyclohexyl group, a PGI 2 derivative of the formula: ##STR11## wherein R 5 represents a lower alkyl group and R 6 represents a pentyl group, a 1-methylpentyl group, a 1-methyl-5-chloropentyl group, a 2-methyl-5-chloropentyl group, a 3-ethylcyclopentyl group, a 3-propylcyclopentyl group, a 3-butylcyclopentyl group, a 3-(2-chloroethyl)cyclopentyl group, a cyclohexyl group, a 4-ethylcyclohexyl group or a cyclohexylmethyl group, or a PGE 1 derivative of the formula: ##STR12## wherein X represents a methylene group or a carbonyl group, and (i) when X represents a methylene group, Y represents an ethylene group or a trans-vinylene group, R 7 represents a carboxyl group or a lower alkoxycarbonyl group and R 8 represents a 2-methylhexyl group or a 1-cyclohexylethyl group, and (ii) when X represents a carbonyl group, Y represents an ethylene group, R 7 represents a carboxyl group, a lower alkoxycarbonyl group, a glycoloyl group or a hydroxymethyl group and R 8 represents a 2-methylhexyl group, a cyclopentyl group, a 3-propylcyclopentyl group or a 3-butylcyclopentyl group, the double bonds between C 13 -C 14 in formulae (I), (II), (III) and (IV) being trans, the configuration at C 5 in formulae II and III being E or Z or a mixture thereof, the hydroxy groups attached to the C 11 position in formulae (I), (II), (III) and (IV) being in α-configuration and the hydroxy groups attached to the C 15 position in formulae (I), (II), (III) and (IV) being in α- or β-configuration, or a mixture thereof, or a cyclodextrin clathrate of a derivative of formula (I), (II), (III) or (IV) or, when R 1 in formula (I) or R 3 in formula (II) represents a hydrogen atom, or when R 7 in formula (IV) represents a carboxy group, a non-toxic salt thereof.